Published in Cancer Res on January 15, 1994
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res (2014) 2.92
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A (1999) 1.87
Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res (2000) 1.69
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet (2002) 1.57
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clin Cancer Res (2015) 1.29
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol (2015) 1.22
Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci U S A (1995) 1.19
Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One (2013) 1.16
Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer (2000) 1.03
Antiestrogens--tamoxifen, SERMs and beyond. Invest New Drugs (1999) 0.95
Endocrine resistance in breast cancer - An overview and update. Mol Cell Endocrinol (2015) 0.93
Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res (2009) 0.93
DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. Br J Cancer (1999) 0.93
Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects. Proteins (2014) 0.88
Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat (2014) 0.87
Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Res (2014) 0.86
Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer (2000) 0.85
Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. Br J Cancer (2000) 0.77
A synthetic oestrogen antagonist, tamoxifen, inhibits oestrogen-induced transcriptional, but not post-transcriptional, regulation of gene expression. Biochem J (1996) 0.76
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. BMC Cancer (2016) 0.75
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene (2016) 0.75
Steroid hormone receptors and their clinical significance in cancer. J Clin Pathol (1995) 0.75
Endocrine treatment of cancer. J R Soc Med (1996) 0.75
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients. Oncotarget (2017) 0.75
Cardiac malformation in neonatal mice lacking connexin43. Science (1995) 5.51
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol (2005) 3.62
In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother (1996) 3.08
The regulatory light chain of nonmuscle myosin is encoded by spaghetti-squash, a gene required for cytokinesis in Drosophila. Cell (1991) 2.76
Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet (2000) 2.72
Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell (1998) 2.64
Signaling events underlying thrombus formation. J Thromb Haemost (2003) 2.07
UNC-73 activates the Rac GTPase and is required for cell and growth cone migrations in C. elegans. Cell (1998) 2.02
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res (1993) 1.98
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Unusual reducing sugar from Coccidioides immitis. J Bacteriol (1970) 1.74
The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol (1998) 1.72
Raised plasma soluble P-selectin in peripheral arterial occlusive disease enhances leukocyte adhesion. Circ Res (2005) 1.64
Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood (1977) 1.62
Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report. Sex Transm Infect (2008) 1.54
Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? Bone Marrow Transplant (2002) 1.49
Drosophila nonmuscle myosin II is required for rapid cytoplasmic transport during oogenesis and for axial nuclear migration in early embryos. Development (1995) 1.49
Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol (2001) 1.48
Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother (2001) 1.47
Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol (2000) 1.45
Erdheim-Chester disease. Case report and review of the literature. Am J Med (1986) 1.44
Primary cryotherapy with salvage external beam radiotherapy for locally recurrent prostate cancer. Clin Oncol (R Coll Radiol) (2008) 1.43
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol (1998) 1.42
Prevalence and incidence of hepatitis B virus infection in STD clinic attendees in Pune, India. Sex Transm Infect (2002) 1.37
Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. Cancer Treat Rep (1979) 1.36
The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. Semin Hematol (1987) 1.34
Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res (1999) 1.32
Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA. Virology (1999) 1.32
Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura. Semin Hematol (1976) 1.28
The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nat Genet (2000) 1.27
Use of autologous growth factors in lumbar spinal fusion. Bone (1999) 1.26
Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood (1998) 1.25
Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob Agents Chemother (1997) 1.25
Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer (2001) 1.20
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19
Neurological manifestations of HIV disease. J Assoc Physicians India (2001) 1.18
TBX6 null variants and a common hypomorphic allele in congenital scoliosis. N Engl J Med (2015) 1.15
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol (1999) 1.15
The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry (1996) 1.15
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res (2001) 1.14
Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol (1996) 1.13
Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer (2005) 1.12
Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst (1993) 1.11
Perceived sources of stress amongst Indian dental students. Eur J Dent Educ (2009) 1.10
Synergistic adhesive interactions and signaling mechanisms operating between platelet glycoprotein Ib/IX and integrin alpha IIbbeta 3. Studies in human platelets ans transfected Chinese hamster ovary cells. J Biol Chem (2000) 1.10
Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. Cancer Res (1999) 1.10
Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. J Infect Dis (1998) 1.08
Thrombotic thrombocytopenic purpura: a review. Prog Hemost Thromb (1982) 1.08
The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. J Biol Chem (1999) 1.06
Prostacyclin therapy of thrombotic thrombocytopenic purpura. Lancet (1980) 1.05
Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leuk Lymphoma (1999) 1.05
Human defensins and cytokines in vaginal lavage fluid of women with bacterial vaginosis. Int J Gynaecol Obstet (2008) 1.05
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant (2000) 1.04
Hemifacial microsomia: a case report. J Indian Soc Pedod Prev Dent (2008) 1.04
Characterization of peptide-oligonucleotide heteroconjugates by mass spectrometry. Nucleic Acids Res (1996) 1.04
Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest (1999) 1.02
Determinants for oral hygiene and periodontal status among mentally disabled children and adolescents. J Indian Soc Pedod Prev Dent (2009) 1.01
Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med (1984) 1.01
Experience with eosin-5'-maleimide as a diagnostic tool for red cell membrane cytoskeleton disorders. Clin Lab Haematol (2003) 1.01
Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles. Antimicrob Agents Chemother (2000) 1.01
Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signature. Oncogene (2011) 1.00
Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res (1998) 0.99
Rubella virus and birth defects: molecular insights into the viral teratogenesis at the cellular level. Birth Defects Res A Clin Mol Teratol (2004) 0.98
8-anilino-1-naphthalene sulfonic acid (ANS) induces folding of acid unfolded cytochrome c to molten globule state as a result of electrostatic interactions. Biochemistry (1999) 0.98
Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase. Proc Natl Acad Sci U S A (1996) 0.98
Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood (2001) 0.97
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol (1999) 0.97
HIV infection among Brazilian transvestites in a prison population. AIDS Patient Care STDS (1996) 0.97
The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J Biol Chem (1995) 0.97
Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood (2000) 0.96
Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy. Cancer (1983) 0.96
Irreducible lateral dislocation of the elbow. J Postgrad Med (2000) 0.96
Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res (2000) 0.95
Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer (1995) 0.95
Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst (1999) 0.94
Posterior cruciate ligament at total knee replacement. Essential, beneficial or a hindrance? J Bone Joint Surg Br (2003) 0.94
Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant (2002) 0.93
Lymphatic filariasis: possible pathophysiological nexus with oxidative stress. Trans R Soc Trop Med Hyg (2006) 0.93
Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology (1998) 0.93
Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. Transplant Proc (2011) 0.92
Growth and intestinal differentiation are independently regulated in HT29 colon cancer cells. J Cell Physiol (1994) 0.92
Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J Biol Chem (2001) 0.92
In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline. Clin Cancer Res (1999) 0.92
High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol (2008) 0.92
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res (2001) 0.91
Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant (2001) 0.91
Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study. Cancer (1983) 0.91
Coronary sinus thrombosis. J Postgrad Med (2003) 0.90
Cytogenetic and array-CGH characterization of a complex de novo rearrangement involving duplication and deletion of 9p and clinical findings in a 4-month-old female. Cytogenet Genome Res (2010) 0.90
Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J Clin Oncol (1988) 0.90
Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice. Leukemia (2010) 0.90
T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology (1999) 0.90
T cell lymphoma occurring in Sjögren's syndrome. Arthritis Rheum (1984) 0.89
Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin Cancer Res (1999) 0.89
Fungal contamination of air conditioning units in operating theatres in India. J Hosp Infect (2005) 0.89
Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Oncogene (2009) 0.89